Recordati has received a takeover offer from private equity group CVC that, if completed, would delist it from the Italian stock exchange.
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
Biogen trumpeted new Phase 2 lupus data on Saturday for a program it hopes will become a pillar of its immunology pipeline. The drug litifilimab



